Literature DB >> 7821892

c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival.

C M Quinn1, J L Ostrowski, S A Lane, D P Loney, J Teasdale, F A Benson.   

Abstract

c-erbB-3 protein expression was investigated immunohistochemically in a series of 97 malignant breast tumours using the monoclonal antibody RTJ1. Twenty-eight cases (28.8%) showed c-erbB-3 overexpression, 31 cases (32%) showed normal levels of c-erbB-3 and 38 cases (39.2%) were c-erbB-3 negative. c-erbB-3 overexpression was positively but not significantly related to negative lymph node status and survival over a 10-year follow-up period.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7821892     DOI： 10.1111/j.1365-2559.1994.tb01324.x

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


  28 in total

1.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 2.  The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.

Authors:  Anne W Hamburger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-19       Impact factor: 2.673

3.  Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.

Authors:  Rebecca S Muraoka-Cook; Laura S Caskey; Melissa A Sandahl; Debra M Hunter; Carty Husted; Karen E Strunk; Carolyn I Sartor; William A Rearick; Wesley McCall; Magdalene K Sgagias; Kenneth H Cowan; H Shelton Earp
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

4.  Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.

Authors:  P M Siegel; E D Ryan; R D Cardiff; W J Muller
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

5.  Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.

Authors:  Jiun-Han Lin; Ching-Hwa Tsai; Jan-Show Chu; Jeou-Yuan Chen; Kenzo Takada; Jin-Yuh Shew
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

Review 6.  Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network.

Authors:  K L Troyer; D C Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

7.  The epidermal growth factor receptor family in breast cancer.

Authors:  Angelos K Koutras; T R Jeffry Evans
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

Review 8.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

Review 9.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

10.  Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

Authors:  A K Koutras; K T Kalogeras; M-A Dimopoulos; R M Wirtz; U Dafni; E Briasoulis; D Pectasides; H Gogas; C Christodoulou; G Aravantinos; G Zografos; E Timotheadou; P Papakostas; H Linardou; E Razis; T Economopoulos; H P Kalofonos; G Fountzilas
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.